Anthim Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Anthim market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to government initiatives for emergency stockpiling, advancements in monoclonal antibody production technologies, heightened global awareness of biological threats, and the increasing need for innovative therapeutic approaches in infectious disease management.

Growth in the forecast period will be driven by improvements in monoclonal antibody production, expanding healthcare infrastructure in emerging markets, and increasing global awareness of biological threat mitigation strategies. Key trends in the forecast period include advanced biopharmaceutical research, growing public-private partnerships in biodefense initiatives, regional diversification in pharmaceutical production, and a focus on streamlined regulatory pathways to accelerate drug approval processes.

The rising prevalence of bacterial infections is expected to drive the growth of the anthim market. Bacterial infections, which occur when harmful bacteria invade the body, multiply, and produce toxins, are on the rise due to factors such as antibiotic overuse, global travel, urbanization, poor hygiene, and healthcare-associated infections. Anthim is a monoclonal antibody used to treat inhalation anthrax, a bacterial infection caused by Bacillus anthracis. It works by neutralizing the anthrax toxin and preventing it from entering cells, thus mitigating its harmful effects. For example, a report from the World Health Organization (WHO) in December 2023 revealed a significant increase in suspected anthrax cases in Zambia, from 42 cases between September 2022 and January 2023 to 684 cases by November 2023, including four deaths. This rising prevalence of bacterial infections, particularly anthrax, is a key factor fueling the growth of the anthim market.

A key trend in the anthim market is the adoption of strategic international contracts, such as public-private partnerships (PPPs), to enhance technology integration and expand market reach. PPPs involve collaborations between government agencies and private pharmaceutical companies to jointly fund, research, and distribute medical treatments, often addressing public health needs. For instance, in April 2022, Heat Biologics, a US-based biotechnology company, secured a $5.65 million contract with the Canadian government through its subsidiary Elusys Therapeutics. This contract involved supplying Anthim for the Canadian National Emergency Strategic Stockpile, marking the drug’s first international procurement aimed at combating anthrax biothreats.

In April 2022, Heat Biologics, a US-based biotechnology company that offers pharmaceuticals, acquired Elusys Therapeutics expanding its biodefense portfolio. The acquisition allowed Heat Biologics to integrate Anthim into its RapidVax platform, enhance its manufacturing capabilities at a new facility in Kansas, and explore expanded global distribution opportunities. These developments highlight the growing strategic importance of Anthim in addressing anthrax threats and its potential for wider global distribution through partnerships and acquisitions.

Major players operating in the anthim market are Elusys Therapeutics Inc, and Hikma Pharmaceutical.

North America was the largest region in the anthim market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anthim report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anthim market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anthim is a monoclonal antibody used to treat inhalational anthrax caused by Bacillus anthracis infection. It works by binding to the anthrax toxin, preventing it from entering cells and causing damage.

The primary types of anthim include adult and pediatric formulations. Anthim (obiltoxaximab) is indicated for use in adults as part of the treatment regimen for inhalational anthrax caused by Bacillus anthracis. Its clinical indications include treating inhalational anthrax, providing post-exposure prophylaxis (PEP) for inhalational anthrax, and its use in both pediatric and adult populations. The various distribution channels include hospitals, drug stores, and other applications.

The anthim market research report is one of a series of new reports that provides anthim market statistics, including anthim industry global market size, regional shares, competitors with a anthim market share, detailed anthim market segments, market trends, and opportunities, and any further data you may need to thrive in the anthim industry. This anthim market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anthim market consists of sales of monoclonal antibodies, injectable solutions and emergency response treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.